vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and SONO TEK CORP (SOTK). Click either name above to swap in a different company.

Arcturus Therapeutics Holdings Inc. is the larger business by last-quarter revenue ($7.2M vs $5.0M, roughly 1.4× SONO TEK CORP). On growth, SONO TEK CORP posted the faster year-over-year revenue change (-3.6% vs -68.4%). SONO TEK CORP produced more free cash flow last quarter ($1.1M vs $-74.5M). Over the past eight quarters, SONO TEK CORP's revenue compounded faster (2.5% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

Sono Tek Corp is a U.S.-headquartered technology firm that designs, produces and sells precision ultrasonic spray coating systems, nozzles and related accessories. Its solutions serve electronics manufacturing, medical device production, energy storage and industrial processing sectors, catering to global commercial clients and research institutions.

ARCT vs SOTK — Head-to-Head

Bigger by revenue
ARCT
ARCT
1.4× larger
ARCT
$7.2M
$5.0M
SOTK
Growing faster (revenue YoY)
SOTK
SOTK
+64.8% gap
SOTK
-3.6%
-68.4%
ARCT
More free cash flow
SOTK
SOTK
$75.6M more FCF
SOTK
$1.1M
$-74.5M
ARCT
Faster 2-yr revenue CAGR
SOTK
SOTK
Annualised
SOTK
2.5%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ARCT
ARCT
SOTK
SOTK
Revenue
$7.2M
$5.0M
Net Profit
$340.0K
Gross Margin
50.2%
Operating Margin
6.4%
Net Margin
6.8%
Revenue YoY
-68.4%
-3.6%
Net Profit YoY
3.1%
24.0%
EPS (diluted)
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
SOTK
SOTK
Q4 25
$7.2M
$5.0M
Q3 25
$17.2M
$5.2M
Q2 25
$28.3M
$5.1M
Q1 25
$29.4M
$5.1M
Q4 24
$22.8M
$5.2M
Q3 24
$41.7M
$5.2M
Q2 24
$49.9M
$5.0M
Q1 24
$38.0M
$4.8M
Net Profit
ARCT
ARCT
SOTK
SOTK
Q4 25
$340.0K
Q3 25
$-13.4M
$423.7K
Q2 25
$-9.2M
$485.0K
Q1 25
$-14.1M
$327.7K
Q4 24
$-30.0M
$274.2K
Q3 24
$-6.9M
$340.7K
Q2 24
$-17.2M
$330.8K
Q1 24
$-26.8M
$156.6K
Gross Margin
ARCT
ARCT
SOTK
SOTK
Q4 25
50.2%
Q3 25
50.2%
Q2 25
51.9%
Q1 25
47.4%
Q4 24
45.1%
Q3 24
48.7%
Q2 24
48.8%
Q1 24
49.1%
Operating Margin
ARCT
ARCT
SOTK
SOTK
Q4 25
6.4%
Q3 25
-96.3%
8.2%
Q2 25
-41.0%
9.4%
Q1 25
-57.3%
5.6%
Q4 24
-146.7%
3.8%
Q3 24
-25.8%
5.5%
Q2 24
-42.4%
4.7%
Q1 24
-80.0%
-0.3%
Net Margin
ARCT
ARCT
SOTK
SOTK
Q4 25
6.8%
Q3 25
-78.4%
8.2%
Q2 25
-32.4%
9.4%
Q1 25
-47.9%
6.4%
Q4 24
-131.8%
5.3%
Q3 24
-16.6%
6.6%
Q2 24
-34.5%
6.6%
Q1 24
-70.5%
3.3%
EPS (diluted)
ARCT
ARCT
SOTK
SOTK
Q4 25
$0.02
Q3 25
$-0.49
$0.03
Q2 25
$-0.34
$0.03
Q1 25
$-0.52
$0.02
Q4 24
$-1.10
$0.02
Q3 24
$-0.26
$0.02
Q2 24
$-0.64
$0.02
Q1 24
$-1.00
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
SOTK
SOTK
Cash + ST InvestmentsLiquidity on hand
$230.9M
$11.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$214.0M
$19.1M
Total Assets
$271.1M
$23.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
SOTK
SOTK
Q4 25
$230.9M
$11.7M
Q3 25
$180.4M
$10.6M
Q2 25
$196.5M
$10.9M
Q1 25
$216.9M
$11.9M
Q4 24
$237.0M
$12.7M
Q3 24
$237.2M
$11.6M
Q2 24
$260.3M
$12.2M
Q1 24
$288.4M
$11.8M
Stockholders' Equity
ARCT
ARCT
SOTK
SOTK
Q4 25
$214.0M
$19.1M
Q3 25
$224.6M
$18.7M
Q2 25
$231.1M
$18.3M
Q1 25
$233.8M
$17.8M
Q4 24
$241.0M
$17.4M
Q3 24
$261.9M
$17.0M
Q2 24
$258.6M
$16.7M
Q1 24
$264.0M
$16.3M
Total Assets
ARCT
ARCT
SOTK
SOTK
Q4 25
$271.1M
$23.9M
Q3 25
$282.3M
$23.2M
Q2 25
$309.3M
$23.4M
Q1 25
$331.8M
$23.4M
Q4 24
$344.1M
$24.3M
Q3 24
$370.7M
$22.9M
Q2 24
$388.6M
$23.6M
Q1 24
$418.8M
$23.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
SOTK
SOTK
Operating Cash FlowLast quarter
$-74.3M
$1.2M
Free Cash FlowOCF − Capex
$-74.5M
$1.1M
FCF MarginFCF / Revenue
-1035.2%
22.8%
Capex IntensityCapex / Revenue
3.2%
1.4%
Cash ConversionOCF / Net Profit
3.56×
TTM Free Cash FlowTrailing 4 quarters
$-811.2K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
SOTK
SOTK
Q4 25
$-74.3M
$1.2M
Q3 25
$-17.2M
$-176.8K
Q2 25
$-5.8M
$-922.3K
Q1 25
$-35.1M
$-674.3K
Q4 24
$-284.0K
$1.3M
Q3 24
$-23.8M
$-418.4K
Q2 24
$-30.1M
$328.0K
Q1 24
$-5.6M
$-278.5K
Free Cash Flow
ARCT
ARCT
SOTK
SOTK
Q4 25
$-74.5M
$1.1M
Q3 25
$-17.3M
$-237.3K
Q2 25
$-974.5K
Q1 25
$-35.3M
$-740.0K
Q4 24
$1.1M
Q3 24
$-23.8M
$-576.1K
Q2 24
$-30.5M
$295.0K
Q1 24
$-5.8M
$-746.6K
FCF Margin
ARCT
ARCT
SOTK
SOTK
Q4 25
-1035.2%
22.8%
Q3 25
-101.1%
-4.6%
Q2 25
-19.0%
Q1 25
-120.1%
-14.5%
Q4 24
20.8%
Q3 24
-57.2%
-11.2%
Q2 24
-61.1%
5.9%
Q1 24
-15.3%
-15.7%
Capex Intensity
ARCT
ARCT
SOTK
SOTK
Q4 25
3.2%
1.4%
Q3 25
1.1%
1.2%
Q2 25
0.0%
1.0%
Q1 25
0.5%
1.3%
Q4 24
0.0%
4.1%
Q3 24
0.2%
3.1%
Q2 24
0.7%
0.7%
Q1 24
0.6%
9.8%
Cash Conversion
ARCT
ARCT
SOTK
SOTK
Q4 25
3.56×
Q3 25
-0.42×
Q2 25
-1.90×
Q1 25
-2.06×
Q4 24
4.70×
Q3 24
-1.23×
Q2 24
0.99×
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons